WO2021202830A3 - Hsp90-binding conjugates and formulations thereof - Google Patents

Hsp90-binding conjugates and formulations thereof Download PDF

Info

Publication number
WO2021202830A3
WO2021202830A3 PCT/US2021/025308 US2021025308W WO2021202830A3 WO 2021202830 A3 WO2021202830 A3 WO 2021202830A3 US 2021025308 W US2021025308 W US 2021025308W WO 2021202830 A3 WO2021202830 A3 WO 2021202830A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
conjugates
hsp90
methods
active agent
Prior art date
Application number
PCT/US2021/025308
Other languages
French (fr)
Other versions
WO2021202830A2 (en
Inventor
Mark T. Bilodeau
Sudhakar Kadiyala
Original Assignee
Tarveda Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarveda Therapeutics, Inc. filed Critical Tarveda Therapeutics, Inc.
Publication of WO2021202830A2 publication Critical patent/WO2021202830A2/en
Publication of WO2021202830A3 publication Critical patent/WO2021202830A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Conjugates comprising an active agent, a HSP90 binding moiety, a chelator, a linker, and a spacer, have been designed. Such conjugates can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.
PCT/US2021/025308 2020-04-01 2021-04-01 Hsp90-binding conjugates and formulations thereof WO2021202830A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063003528P 2020-04-01 2020-04-01
US63/003,528 2020-04-01

Publications (2)

Publication Number Publication Date
WO2021202830A2 WO2021202830A2 (en) 2021-10-07
WO2021202830A3 true WO2021202830A3 (en) 2021-11-04

Family

ID=77930053

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/025308 WO2021202830A2 (en) 2020-04-01 2021-04-01 Hsp90-binding conjugates and formulations thereof

Country Status (1)

Country Link
WO (1) WO2021202830A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024038137A1 (en) * 2022-08-18 2024-02-22 Mexbrain Medical use of functionalized polymer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170128580A1 (en) * 2012-04-16 2017-05-11 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
WO2018236793A1 (en) * 2017-06-20 2018-12-27 Tarveda Therapeutics, Inc. Targeted therapeutics

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170128580A1 (en) * 2012-04-16 2017-05-11 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
WO2018236793A1 (en) * 2017-06-20 2018-12-27 Tarveda Therapeutics, Inc. Targeted therapeutics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem compound ANONYMOUS : "Ganetespib ", XP055870200, retrieved from NCBI Database accession no. 135564985 *

Also Published As

Publication number Publication date
WO2021202830A2 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
WO2020126609A3 (en) Antibody drug conjugates (adc) containing saponin
Santi et al. Macromolecular prodrug that provides the irinotecan (CPT-11) active-metabolite SN-38 with ultralong half-life, low C max, and low glucuronide formation
NZ745069A (en) Pyrrolobenzodiazepines and conjugates thereof
WO1999067284A3 (en) Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
WO2020236825A8 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
GR20000100384A (en) Use of cisplatin and other drugs or genes encapsulated into liposomes for the treatment of human cancers
van Acker et al. 7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week
WO2014081299A1 (en) Activatable liposomes
WO2004111192A3 (en) Targeted delivery to legumain-expressing cells
WO2006060533A3 (en) Conjugates of 1, 8-bis-naphthalimides with an antibody
EP0954340A4 (en) Targeted combination immunotherapy of cancer
WO2006113623A3 (en) Elimination of heterogeneous or mixed cell population in tumors
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
CA2910494C (en) Insulin-oligomer conjugates, formulations and uses thereof
WO2003084470A3 (en) Compositions and methods for targeted biological delivery of molecular carriers
WO2002002147A3 (en) Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery
WO2006065888A3 (en) Targeted iron chelator delivery system
Zhang et al. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas
Inoue et al. CM-dextran-polyalcohol-camptothecin conjugate: DE-310 with a novel carrier system and its preclinical data
WO2021202830A3 (en) Hsp90-binding conjugates and formulations thereof
CA3198996A1 (en) Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
MX2022009819A (en) Anti-cd137 antigen-binding molecule for use in cancer treatment.
GB9908195D0 (en) Treatment of intracellular infection
WO2021014026A3 (en) Bioactive saponin linked to a functional moiety
MX2021011703A (en) Compositions and methods for altering macrophage phenotype.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21781932

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21781932

Country of ref document: EP

Kind code of ref document: A2